

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/072,525	02/05/2002	Karla Robotti	10011206	2898
22878	7590 11/04/2003		EXAMINER	
	ECHNOLOGIES, INC.	NGUYEN, QUANG		
INTELLECTUAL PROPERTY ADMINISTRATION, LEGAL DEPT. P.O. BOX 7599 M/S DL429 LOVELAND, CO 80537-0599			ART UNIT	PAPER NUMBER
			1636	
			DATE MAILED: 11/04/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/072,525	ROBOTTI, KARLA				
Office Action Summary	Examiner	Art Unit				
	Quang Nguyen, Ph.D.	1636				
Th MAILING DATE of this communication appeared for Reply		ith the correspondenc address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute  - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	— 136(a). In no event, however, may a ly within the statutory minimum of thir will apply and will expire SIX (6) MOR e, cause the application to become Al	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ Th						
3) Since this application is in condition for allow closed in accordance with the practice under <b>Disposition of Claims</b>	•	• •				
4) Claim(s) 1-59 is/are pending in the application	n.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-59 are subject to restriction and/or	election requirement.					
Application Papers	·					
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) acce	pted or b) objected to by t	the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Ex	kaminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority document	ts have been received.					
2. Certified copies of the priority document	ts have been received in A	Application No				
3. Copies of the certified copies of the prio application from the International Bu * See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).					
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language pro	ovisional application has b	een received.				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)				

#### **DETAILED ACTION**

Page 2

Claims 1-59 are pending in the present application, and they are subjected to the following restrictions.

#### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

### **Group Restrictions**

- I. Claims 1-56 and 58-59, drawn to a method for immobilizing a biological molecule in a porous inorganic matrix, a method for preparing a microanalytical device comprising the same entrapped or immobilized biological molecule, and a method of using the same microanalytical device, wherein the biological molecule is a polynucleotide, a gene, or a gene fragment, classified in class 435, subclass 6; class 436, subclass 527.
- II. Claims 1-56 and 58-59, drawn to a method for immobilizing a biological molecule in a porous inorganic matrix, a method for preparing a microanalytical device comprising the same entrapped biological molecule, and a method of using the same microanalytical device, wherein the biological molecule is an enzyme or an antibody or a coagulation modulator or a cytokine or an endorphin or a peptidyl hormone or a kinin or a receptor or a solubilized membrane protein, classified in class 435, subclasses 4, 7.1; class 436, subclass 527, for examples.

Application/Control Number: 10/072,525

Art Unit: 1636

- III. Claims 1-56 and 58-59, drawn to a method for immobilizing a biological molecule in a porous inorganic matrix, a method for preparing a microanalytical device comprising the same entrapped biological molecule, and a method of using the same microanalytical device, wherein the biological molecule is a cell membrane or a membrane fragment, classified in class 435, subclass 7.2; class 436, subclass 527.
- IV. Claims 57 and 59, drawn to a microanalytical device comprised of a substrate and at least one feature particulates of sol-gel having a diameter of from about 10  $\mu$ m to about 80  $\mu$ m, classified in class 436, subclass 527.

Claims 1-41, 43-56 and 58-59 link patentably distinct inventions of Groups I to III that lack unity of invention. This is because a biological molecule entrapped in a porous inorganic matrix comprises <u>nucleic acids</u> (e.g., a polynucleotide, a gene, or a gene fragment), <u>proteins</u> (e.g., an enzyme or an antibody or a coagulation modulator or a cytokine or an endorphin or a peptidyl hormone or a kinin or a receptor or a solubilized membrane protein) and cell fragments or membrane fragments that are distinct in chemical compositions having different biological activities, and the methods for entrapping these biological molecules and for utilizing these distinct compositions require different technical considerations for achieving the desired end-results. <u>It is noted that the activity of the immobilized or entrapped biological material is sensitive to the preparation and conditions employed during the use of the sol-gel. Since the operation, function and effects of these different methods are different and distinct one from the other, the inventions of these different, distinct groups are capable of</u>

Application/Control Number: 10/072,525

Art Unit: 1636

supporting separate patents. Additionally, as set forth in MPEP 803.02, unity of invention exists if all species recited in a claim (1) shows a common utility, and (2) share a substantial structural feature disclosed as being essential to that utility.

Upon the allowance of the linking claims, the restriction requirement as to the linked invention shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims or the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-132(CCPA 1971). See also MPEP 804.01.

The above inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I to III are distinct methods involving different starting biological materials being immobilized or entrapped within a porous inorganic matrix and that they require different technical considerations for achieving the desired endresults. The microanalytical device of Group IV is distinct from any of the microanalytical devices of Groups I to III because it does not contain any biological material being immobilized or entrapped within a sol-gel or a porous inorganic matrix.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and separate search requirements, it would be unduly burdensome for the examiner to search and/or consider the patentability of all the inventions in a single application. Therefore, restriction for examination purposes as indicated is proper.

## **Species Restriction**

Should Applicant elects Group II, claims 1 and 41 comprise the following patentably distinct species:

(a) enzymes, (b) antibodies, (c) coagulation modulators, (d) cytokines, (e) endorphins, (f) peptidyl hormones, (g) kinins, (h) receptors and (i) solubilized membrane proteins.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Additionally, should Applicant elects the species (a) above, claims 1, 41-42 comprise the following patentably distinct species:

## A specific enzyme species recited in the Markush group of claim 42.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Application/Control Number: 10/072,525 Page 6

Art Unit: 1636

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17 (h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (703) 308-8339.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, Gerald Leffers, Jr., Ph.D., may be reached at (703) 305-6232, or SPE, Irem Yucel, Ph.D., at (703) 305-1998.

Quang Nguyen, Ph.D.

PRIMARY EXAMINER